



Express Mailing Label No.: EV 493490438 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE BOARD OF PATENT APPEALS AND INTERFERENCE'S**

In re application of: Harry Meade et al.  
Serial No: 09/012,904  
Filed: January 1, 1998  
For: TRANSGENIC PRODUCTION OF ANTIBODIES IN MILK  
Art Unit: 1636  
Examiner: Celine X. Qian  
Attorney Docket Number: G0744.70014US02

**AMENDED APPEAL BRIEF**

Mail Stop Appeal Brief - Patents  
Assistant Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice of Non-Compliant Appeal Brief mailed August 9, 2006, Appellants submit the following amended Appeal Brief. This Amended Appeal Brief is accompanied by a check to cover the five-month extension of time fee for a small entity.

If any additional fees are required, or if any overpayment is to be credited, please charge our Deposit Account 23/2825.

This Amended Appeal Brief contains the items required by 37 C.F.R. § 41.37(c)(1), in the order indicated therein.

(i) **REAL PARTY IN INTEREST**

The real party in interest is GTC Biotherapeutics, Inc., the assignee of record.

(ii) **RELATED APPEALS AND INTERFERENCES**

To the best of Appellants' knowledge, there are no appeals or interferences that may be related to, directly affect, or be directly affected by this appeal.

**(iii) STATUS OF CLAIMS**

Claims 19, 21, 25-27 and 29-35 are pending in the application. Claims 31-35 are withdrawn as being directed to non-elected matter, so claims 19, 21, 25-27, and 29-30 are on appeal. Claims 1-18, 20, 22-24, and 28 were cancelled during prosecution. No other claims were introduced during prosecution.

**(iv) STATUS OF AMENDMENTS**

No amendments have been filed subsequent to the Final Office Action mailed April 20, 2005.

## **(v) SUMMARY OF THE CLAIMED SUBJECT MATTER**

The claims on appeal are directed to a DNA construct for producing recombinant immunoglobulin molecules in the milk of transgenic non-human mammals, as well as cells comprising the DNA. The claimed invention was developed despite the known problems that transgenic animals have with the expression of fusion proteins generally, and the difficulties associated with the production and assembly of biologically active immunoglobulins specifically. [Specification at p. 3, lines 1-10.]

Two teachings in the art counseled against Appellants' invention. First, those of ordinary skill in the art had confronted certain difficulties in producing immunoglobulins in cells other than B-lymphocytes. These difficulties included the following: 1) both heavy and light chains of the desired immunoglobulin must be co-expressed at appropriate levels; 2) nascent immunoglobulin polypeptides undergo a variety of co- and post-translational modifications that may not occur with sufficient fidelity or efficiency in in vitro cell cultures; 3) immunoglobulins require accessory proteins for their assembly; 4) the synthetic and expression capacity of in vitro cell cultures may be inadequate for the large amount of antibody needed commercially; and 5) the expressed recombinant immunoglobulins may be unstable in the extracellular milieu of a foreign cell. [Specification at p. 1, lines 8-22.]

Second, those of ordinary skill in the art had only been able to express single chain polypeptides in the milk of transgenic animals. There had not been a report of successful expression in transgenic milk of a molecule that required multimerization and/or assembly, such as an immunoglobulin. [Specification at p. 2, lines 19-34.]

At the time of Appellants' invention, numerous scientists had attempted to express immunoglobulins in transgenic animals, but those attempts were limited to expression in blood. [Specification at p. 2, lines 1-5.] Given the difficulties in expressing antibodies recombinantly, combined with the difficulties of expressing multimeric proteins in transgenic milk, those of ordinary skill in the art were not motivated to attempt the production of immunoglobulins in transgenic milk.

Appellants' invention, thus, provides a DNA construct for providing a heterologous immunoglobulin in the milk of a non-human transgenic mammal (claim 19). Various promoters can be used (claims 21 and 25), as well as a certain restriction site (claim 26), and a certain non-coding sequence (claim 27). The claims on appeal are also directed to a mammary epithelial cell comprising such a DNA construct (claims 29-30).

**(vi) GROUNDS OF REJECTION TO BE REVIEWED ON APPEAL**

A. Whether claims 19 and 25-27 are unpatentable under 35 U.S.C. § 103(a) over Meade et al.<sup>1</sup>, taken with DeBoer et al.<sup>2</sup>

B. Whether claim 21 is unpatentable under 35 U.S.C. § 103(a) over Meade et al., taken with DeBoer et al., and further in view of Bischoff et al.<sup>3</sup>, Buhler et al.<sup>4</sup>, Gordon et al.<sup>5</sup>, Ebert et al.<sup>6</sup>, and Sinnakre et al.<sup>7</sup>

C. Whether claims 19, 21, 25-27, and 30 are unpatentable under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement.

D. Whether claims 19, 21, 25-27, and 30 are unpatentable under 35 U.S.C. § 112, second paragraph, as being indefinite.

---

<sup>1</sup> US 4,873,316

<sup>2</sup> US 5,663,076

<sup>3</sup> FEBS Letters, 305: 265-268, 1992.

<sup>4</sup> Bio/Technology, 8: 835-838, 1991.

<sup>5</sup> Bio/Technology, 5: 1183-1187, 1987.

<sup>6</sup> Bio/Technology, 8: 140-143, 1990.

<sup>7</sup> FEBS Letters, 284: 19-22, 1991.



**(viii) ARGUMENT**

**A. Claims 19 and 25-27 are patentable under 35 U.S.C. § 103(a) over Meade et al., taken with DeBoer et al.**

The rejection of claims 19 and 25-27 under 35 U.S.C. §103(a) as being obvious in light of Meade et al. and DeBoer et al. should be reversed. As discussed above, the prior art did not teach the successful transgenic production of immunoglobulins in milk for two reasons. First, recombinant antibodies were hard to produce at the time of the invention in cells other than B-cells because of their complex nature, comprising multiple chains that need to be assembled in the proper orientation and multimerized. Specifically, 1) both heavy and light chains of the desired immunoglobulin must be co-expressed at appropriate levels; 2) nascent immunoglobulin polypeptides undergo a variety of co- and post-translational modifications that may not occur with sufficient fidelity or efficiency in in vitro cell cultures; 3) immunoglobulins require accessory proteins for their assembly; 4) the synthetic and expression capacity of in vitro cell cultures may be inadequate for the large amount of antibody needed commercially; and 5) the expressed recombinant immunoglobulins may be unstable in the extracellular milieu of a foreign cell. [Specification at p. 1, lines 8-22.]

Second, although proteins had been expressed transgenically in milk, only simple proteins had been. Nobody been able to express a molecule that required multimerization and/or assembly, such as an immunoglobulin. [Specification at p. 2, lines 19-34.]

Both Meade et al. and DeBoer et al. list immunoglobulins in a laundry list of proteins that might be expressed in their methods. [Meade et al. at col. 3, lines 38-39; DeBoer et al. at col. 7, line 8.] That speculation, however, does not render the invention obvious because they do nothing to change the lack of motivation in the art. One of ordinary skill in the art would not have been motivated to attempt to express an immunoglobulin in the milk of a transgenic mammal because of the known difficulties with expressing immunoglobulins in cells other than B-cells, combined with the failure of the art to have expressed a complex, multichain protein in transgenic milk.

While both Meade et al. and DeBoer et al. are US patents, which are relevant as prior art for all that they contain, an obviousness rejection still requires a reasonable expectation of

success. The Examiner has not shown that one of ordinary skill in the art would have had a reasonable expectation of success in producing an immunoglobulin in transgenic milk, and the speculation in Meade et al. and DeBoer et al., which actually produce simple proteins, that immunoglobulins might be produced in that way would not have changed that lack of expectation.

Even if one of ordinary skill in the art would have been motivated to combine the teachings of Meade et al. and DeBoer et al. with a reasonable expectation of success, the combination would not render the claimed invention obvious. Meade et al. fails to provide or teach the following:

- I. Meade et al. fails to teach or suggest that expressing the light chain and heavy chain of an immunoglobulin separately by using a mammary epithelial cell comprising at least two vectors, one encoding the heavy chain and one encoding the light chain. Meade et al., simply fails to contemplate expressing these chains separately;
- II. Meade et al., fails to teach a separate construct for the light chain and the heavy chain for the production of a single immunoglobulin species;
- III. Meade et al, fails to indicate that the use of two separate vectors can result in a cell capable of producing an assembled, functional immunoglobulin in milk;
- IV. Meade et al., fails to disclose a unique restriction between the promoter and the 3' non-coding sequence, wherein the immunoglobulin coding sequence is inserted into the restriction site;
- V. Meade et al. fails to teach that the claimed construct should have a unique restriction site in between the promoter and the 3' untranslated region into which an immunoglobulin protein-encoding sequence is inserted; and,

VI. Meade et al., fails to teach the unique construction of the restriction site—such that it has a coding sequence inserted into the site- that then allows for a vector which can easily be modified, without the need for cleaving the remaining construct to insert various immunoglobulin chains is an improvement over the prior art. This construction allows for easier expression of a variety of different immunoglobulin coding sequences. Thus, the use a unique restriction site into which the immunoglobulin coding sequence is inserted, adapts to the unique features of expressing immunoglobulins.

DeBoer et al. does not provide what Meade lacks. Importantly, neither Meade et al. nor DeBoer et al. teach or suggest the claimed construct having a unique restriction site in between the promoter and the 3' untranslated region into which an immunoglobulin protein-encoding sequence is inserted. DeBoer also fails with regard to each and every other element called out above as deficient in Meade et al. Respectfully, the lack of even one element I – VI as provided above is sufficient to prevent an obviousness rejection from being maintained.

Respectfully, and to clarify the Appellants' position DeBoer et al. does not make up for any of the other deficiencies of the Meade et al. reference. Specifically, the Examiner asserts that DeBoer et al. at Column 30 lines 45-50 and Figure 7E provides for the development of a construct having a casein promoter and a 3' non-coding sequence, and unique restriction sites, including XhoI, between the promoter and the 3' coding sequence. However, neither the textual citation of DeBoer or the Figure demonstrates a mammary gland specific promoter and a 3' non-coding region wherein there is a unique restriction site into which an immunoglobulin-coding sequence has been inserted. Therefore, this citation simply does not present the elements of the current invention regarding the production fully-functional, fully-assembled immunoglobulins in transgenic mammalian milk. It does not teach this modification of the prior art. Moreover, it does not teach any combination with Meade et al.

Accordingly, the rejection of claims 19 and 25-27 under 35 U.S.C. §103(a) as being unpatentable over Meade et al., in view of DeBoer et al. should be reversed.

**B. Claim 21 is patentable under 35 U.S.C. § 103(a) over Meade et al., taken with DeBoer et al., and further in view of Bischoff et al., Buhler et al. , Gordon et al. , Ebert et al. , and Sinnakre et al..**

Appellants do not contend that the limitations of claim 21 render it separately patentable from claims 19 and 25-27. Accordingly, the rejection of claim 21 under 35 U.S.C. § 103(a) over Meade et al., taken with DeBoer et al., and further in view of Bischoff et al., Buhler et al. , Gordon et al. , Ebert et al. , and Sinnakre et al. should be reversed for the reasons discussed regarding rejection A above.

**C. Claims 19, 21, 25-27, and 30 are patentable under 35 U.S.C. § 112, first paragraph.**

The rejection of claims 19, 21, 25-27, and 30 under 35 U.S.C. § 112, first paragraph, as failing to comply with the written description requirement should be reversed. The Examiner contends that the specification does not support the individual expression of each immunoglobulin chain (heavy coding region and light coding region) in the same construct. However, original claim 1 recites cells that “contain recombinant DNA sequences encoding immunoglobulin heavy and light chains, wherein said sequences are operatively linked at their 5’ termini to a promoter sequence.” This supports the individual expression of each immunoglobulin chain in the same construct. Each “recombinant DNA sequence” has a 5’ termini, and they are “linker at their 5’ termini to a promoter sequence.” Thus, a promoter sequence is linked to the heavy chain 5’ terminus, and a promoter sequence is linked to the light chain 5’ terminus.

Perhaps the Examiner believes that this original claim contemplated a single promoter linked to the heavy chain sequence and the light chain DNA sequence serially, with one promoter linked to the 5’ terminus of the heavy chain sequence and the light chain sequence linked at its 5’ terminus to the 3’ terminus of the heavy chain sequence. But that is not what original claim 8 recites. Claim 8 recites that the heavy chain and the light chain “sequences are operatively linked at their 5’ termini to a promoter sequence.” If only one of the chains was to

be linked to the promoter, and the other chain was to be linked to the first chain, “their 5’ termini” would not be plural. A construct with the heavy chain sequence operatively linked to a promoter at its 5’ terminus and a light chain operatively linked to a promoter at its 5’ terminus does allow each chain to be expressed individually. Accordingly, the rejection of claims 19, 21, 25-27, and 30 as being unpatentable under 35 U.S.C. § 112, first paragraph, for lack of written description should be reversed.

**D. Claims 19, 21, 25-27, and 30 are patentable under 35 U.S.C. § 112, second paragraph.**

The Examiner rejected claims 19, 21, 25-27, and 30 under 35 U.S.C. § 112, second paragraph, as being indefinite because it is unclear whether the two last wherein clauses are both required or whether they are alternatives. Alternative limitations in claims are the exception, which must be clearly identified as such. *See* MPEP § 2173.04(h) Alternative Limitations (“Alternative expressions are permitted if they present no ambiguity”). Appellants have not clearly identified these two wherein clauses as alternatives, so there is no reason to even suspect that they are alternatives. Both clauses are required.

Appellants submit that the use of multiple wherein clauses is commonly accepted in patent law to require that all wherein clauses be met. Indeed, claim 19 itself contains a total of 6 wherein clauses, only one of which is linked with a conjunctive “and.” The Examiner has not found the other 3 wherein clauses without a conjunctive “and” to render the claims indefinite, and similarly the last two wherein clauses do not render the claims indefinite.

While claim 19 may not be artfully drafted, Appellants submit that one skilled in the art would understand that the claim requires that the cell meeting the limitations of the wherein clause following the transitional phrase “further comprising.” Accordingly, the claim is not indefinite.

Accordingly, the rejection of claims 19, 21, 25-27, and 30 under 35 U.S.C. § 112, second paragraph, as being indefinite should be reversed.

**(ix) CONCLUSION**


Each of the four rejections on appeal should be reversed for the reasons set forth above, resulting in allowance of claims 19, 21, 25-27, and 29-30.

Respectfully submitted,

Date: \_\_\_\_\_

2/9/07

By: \_\_\_\_\_



Michael T. Siekman  
Registration No. 36,276  
WOLF, GREENFIELD & SACKS, P.C.  
Federal Reserve Plaza  
600 Atlantic Avenue  
Boston, Massachusetts 02210-2206  
(617) 646-8000

## CLAIMS APPENDIX

1-18. (Cancelled)

19. (Previously Presented) A DNA construct for providing a heterologous immunoglobulin in the milk of a non-human transgenic mammal comprising a promoter sequence that results in the preferential expression of a protein-coding sequence in mammary gland epithelial cells, an immunoglobulin protein-coding sequence, a 3' non-coding sequence; and a unique restriction site between the promoter and the 3' non-coding sequence, wherein the immunoglobulin protein-coding sequence is inserted into the restriction site; and wherein said DNA construct is integrated into the genome of said mammal in such a way that said protein-coding sequence is expressed in the mammary gland of said mammal, and secreted from said mammary gland in the milk of said mammal; and,

wherein the expressed immunoglobulin protein sequence is primarily or completely of human origin, wherein each coding region may be expressed individually and,

wherein the immunoglobulin protein-coding sequence encodes a heavy chain coding region;

wherein said immunoglobulin protein-coding sequence encodes a light chain coding region.

20. (Cancelled)

21. (Previously Presented) The construct of claim 19 wherein said promoter is selected from the group consisting of a beta lactoglobulin promoter, a whey acid protein promoter, and the lactalbumin promoter.

22-24. (Cancelled)

25. (Previously Presented) The construct of claim 19 wherein said promoter is a casein promoter.

26. (Previously Presented) The construct of claim 19, wherein the restriction site is an XhoI restriction site.

27. (Previously Presented) The construct of claim 19, wherein the 3' non-coding sequence is a 3' non-coding region from a mammary-specific gene.

28. (Cancelled)

29. (Previously Presented) A mammary gland epithelial cell comprising the construct of claim 19 and a construct comprising an immunoglobulin protein-coding sequence which encodes both a light chain and a heavy chain, operatively linked to a promoter sequence that results in the preferential expression of the protein-coding sequence in mammary gland epithelial cells, wherein the cell expresses the light and heavy chains separately and secretes a heterologous, assembled immunoglobulin comprising the light and heavy chains.

30. (Previously Amended) A mammary gland epithelial cell comprising the construct of claim 19 further comprising wherein the cell expresses the light and heavy chains separately and the sequences so expressed are fully human sequences; and,

wherein said promoter sequence is selected from a group consisting of: beta lactoglobulin promoter, casein promoter, whey acid protein promoter, and the lactalbumin promoter.

31-35 (Withdrawn)



## EVIDENCE APPENDIX

None

## **RELATED PROCEEDINGS**

None